Cefonicid
A second-generation cephalosporin antibiotic with a prolonged half-life that allows for once-daily intramuscular dosing, used for mild to moderate infections and surgical prophylaxis. It is effective against many gram-positive and gram-negative bacteria. Its extended dosing interval offers practical convenience in outpatient parenteral antibiotic therapy.
Moleküler Ağırlık
542,6000 g/mol
LogP
-1,90
TPSA
264,00 Ų
Lipinski RO5
Başarısız
Etki Mekanizması
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
2D Yapı
Cite this structure
Embed this structure
SMILES
O=C(O)C1=C(CSc2nnnn2CS(=O)(=O)O)CS[C@@H]2[C@H](NC(=O)[C@H](O)c3ccccc3)C(=O)N12
InChI
InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1
Molecular Formula
C18H18N6O8S3
HBD / HBA
4 / 13
Döndürülebilir Bağlar
9
Ağır Atomlar
35
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A second-generation cephalosporin antibiotic with a prolonged half-life that allows for once-daily intramuscular dosing, used for mild to moderate infections and surgical prophylaxis. It is effective against many gram-positive and gram-negative bacteria. Its extended dosing interval offers practical convenience in outpatient parenteral antibiotic therapy.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cefonicid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1601. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 43594. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefonicid"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefonicid/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefonicid/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefonicid/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefonicid"></drugfyi-drug>